Pfizer Inc. (PFE) Earnings Call Transcript & Summary
November 3, 2026
What were the key takeaways from Pfizer Inc.'s November 3, 2026 earnings call?
Pfizer Inc. reported a strong third quarter for 2026, with revenues of $16.6 billion, reflecting a 7% operational growth in non-COVID products. Adjusted diluted EPS was $0.87, exceeding expectations and prompting management to raise full-year revenue guidance by $1.5 billion to a range of $62 billion to $64 billion. The company also raised its adjusted EPS guidance to a range of $2.95 to $3.05, indicating confidence in its ongoing operational execution and pipeline advancements.
What topics did Pfizer Inc. cover?
- Revenue Growth in Non-COVID Products: Pfizer's non-COVID product revenues grew by 7% operationally, driven by strong performance in key brands. CEO Albert Bourla stated, "Our excellent commercial execution including 32% operational revenue growth in the quarter for our launched and acquired products shows the underlying strength of our business."
- Pipeline Advancements and R&D Focus: Management highlighted significant progress in their R&D pipeline, with multiple Phase III trials underway and a focus on high-value therapeutic areas. Bourla noted, "We believe that we are on a pathway to the next stage of meaningful growth."
- Guidance Increase: Pfizer raised its full-year 2026 revenue guidance by $1.5 billion and adjusted EPS guidance by $0.10, reflecting strong performance and confidence in future growth. CFO Cecile Guegan remarked, "This year's performance gives us the confidence to raise our full year 2026 revenue guidance as well as raise and narrow our adjusted diluted EPS guidance."
- Cost Management and Efficiency Initiatives: The company is on track to deliver $7.2 billion in net savings from cost improvement programs by the end of 2026, with an additional $2.5 billion expected from 2027 to 2029. Guegan stated, "We are improving operating efficiency while enabling increased pipeline investment in program waiver offers a greatest potential for patients and shareholders."
- Impact of COVID-19 Product Declines: Lower revenues from COVID-19 products were noted, impacting overall growth. Guegan mentioned, "offset by lower revenues from our COVID-19 products," indicating challenges in this segment.
What were Pfizer Inc.'s November 3, 2026 results?
- Revenue: $16.6 billion
- Adjusted Diluted EPS: $0.87 (exceeded our expectation)
- Adjusted Gross Margin: 77%
- Full Year 2026 Revenue Guidance: $62 billion to $64 billion (raised by $1.5 billion at the midpoint)
- Full Year 2026 Adjusted EPS Guidance: $2.95 to $3.05
- Operating Cash Flow: $8.8 billion
Pfizer's strong performance in Q3 2026, characterized by robust revenue growth in non-COVID products and a positive outlook for its pipeline, supports a favorable investment thesis. However, the decline in COVID-19 product revenues and competitive pressures present risks that investors should monitor closely. Future catalysts include ongoing clinical trial results and potential regulatory approvals that could enhance the company's growth trajectory.
Earnings Call Speaker Segments
Francesca DeMartino here, Pfizer's Chief Investor Relations Officer, welcoming everyone to our earnings call this morning. We on the Pfizer team appreciate you taking part. You can listen to this call through the audio webcast at pfizer.com. Our third quarter 2026 results came out earlier today through a press release posted on our website, pfizer.com. Joining me are Dr. Albert Bourla, Chairman and CEO; Cecile Guegan, our CFO; and Chris Boshoff, our Chief Scientific Officer. Once they finish their prepared remarks, we'll take questions from callers. Our leadership team members will be on hand for the Q&A session. To kick things off, a quick reminder: this session will include forward-looking statements and coverage of some non-GAAP financial measures. Please take a look at the disclaimers in our slide deck, the press release distributed this morning, and the disclosures in our SEC filings — all of which can be found on the investor relations section of pfizer.com. Any forward-looking statements made today carry significant risks and uncertainties, are valid only as of the original date of this call, and we have no duty to update or revise them. With that said, I'll hand things over to Albert.
Thanks, Francesca. Morning, everyone — glad to have you with us today. I'm pleased with what Pfizer achieved in yet another strong quarter. Our commercial organizations performed at a very high level, and the 32% operational revenue growth for our loans and acquired products this quarter shows the underlying strength of our business. Remaining disciplined with our finances and steadily boosting productivity is driving efficiency and benefiting our margins. As our high-value R&D programs keep advancing, we believe we're heading toward the next stage of significant growth. Before I continue, I'd like to welcome Cecile Guegan as our Chief Financial Officer. Cecile has more than 25 years of leadership experience in finance and a demonstrated history of generating fresh avenues for growth. During our worldwide search, she distinguished herself thanks to her know-how, her thorough understanding of Pfizer and our sector, and the strategic foresight that I believe will assist Pfizer in unlocking enduring long-term value for patients and shareholders. I am eager to work alongside Cecile, and I have confidence that she will support us in carrying out our plans with rigor and drive in this coming chapter <<inaudible>>; let me now go over a number of key points regarding the progress we made this quarter. As you're aware, across the past several years we've committed nearly $80 billion toward deals that brought us essential products fueling today's commercial momentum as well as platforms holding transformative promise. Roughly 80% of that spending went toward Seagen, Metsera and Biohaven, and we're progressing well when it comes to extracting maximum value from each. We're happy with how our acquired products are performing overall — they rose 37% operationally this quarter. Our legacy Seagen portfolio climbed 39% year-over-year in the U.S. during the quarter, powered by Padcev's strong showing; combining Seagen's medicines with our commercial organization's expanded reach has strengthened our footing within the oncology community. Physicians and care teams now have a wider range of choices and greater expertise from us, which benefits patients and fuels Pfizer's growth. Seagen didn't just reinforce our commercial standing. It also broadened our capacity to uncover oncology breakthroughs, and when the acquisition closed, it doubled the size of our early-stage pipeline. Across our late-stage development programs, we're moving forward potential antibody drug conjugates that might deliver meaningful improvements for patients with cans. The speed of progress over the past year pleases me, including our extensive clinical development program spanning our obesity portfolio. Our 2026 roadmap includes moving forward with ten Phase III trials—some active, some planned—and one of those will test switching patients from currently approved weekly treatments to berobenatide, our investigational monthly GLP-1 peptide. Enrollment has moved along strongly throughout our pivotal berobenatide program and also in our amylin combination program, whose Phase IIb study has now filled all its slots. We're aiming toward the first of several possible approvals for berobenatide in 2028, and our go-to-market planning is already well advanced. Pfizer has also gained strategically important ground through Biohaven. Nurtec delivered 33% growth operationally this quarter, driven by underlying demand and excellent commercial execution. We believe there is a genuine chance to support migraine patients and for the oral CGRP class to serve as a major growth engine, even while we navigate market dynamics in a competitive space. We hold the lead in the oral CGRP class within the U.S. and are striving to carry that position into international markets; international growth is materializing as additional patients can now access this treatment in key countries, among them the U.K., Italy and Japan. We are likewise heartened by robust uptake wherever we can broaden access. Execution in R&D during 2026 has been solid; and we keep prioritizing the highest value opportunities for patients and for future growth throughout our four therapeutic focus areas. The progress we've made is remarkable and shows the momentum our strategy has generated. In the past few months, we obtained two significant regulatory decisions, a single important pivotal readout, and eight starts of key pivotal studies, along with compelling data that we shared at a number of recent medical congresses. We're extremely excited about the pipeline opportunities in the areas that are our strategic focus and where we have commercial strength. That includes late-stage programs spanning tumor types in oncology—multiple myeloma, breast cancer and lung cancer among them—as well as within inflammation and immunology and, naturally, in neococal vaccines. Chris is going to give you more detail about the advances we've made recently across various end months. Disciplined prioritization and accelerated execution are what our pipeline strategy is built on. We feel sure that we're advancing the biggest opportunities we have for helping patients in the future and for growth. As of today, we're raising our guidance for full-year 2026 revenue and adjusted earnings per share. That reflects how strongly we performed in the third quarter and our confidence in carrying out our strategy, along with our financial discipline and the ongoing progress in our R&D pipeline; we think Pfizer is positioned well to generate growth as the decade comes to a close and to produce lasting value for patients and shareholders over the long run; we've put AI to work across our business, aiming to boost efficiency in manufacturing and to improve how we engage with physicians and patients. Regarding R&D, our efforts are focused on accelerating innovation through quicker target validation and improved selection of molecules and biomarkers. The recent debut of GENESIS—a novel pharmacovigilance platform—shows how committed we are to applying advanced AI and intelligent automation to safety monitoring on a global scale. Ordinarily, this entails a drawn-out manual effort across more than 600 products in over 120 countries. GENESIS absorbs the administrative work so that our safety scientists can devote their time to what matters most: evaluating causality, identifying safety signals, and safeguarding patients. With that, I'll hand things over to Cecile.
Thank you, Albert, and good morning. It's a proud moment for me to address you as Pfizer's CFO. I look forward to working closely with the executive leadership team and to leading a finance organization of the highest caliber. I'm truly excited about everything we can accomplish together, and I'll bring financial discipline to this role, concentrating on turning Pfizer's scientific and commercial momentum into lasting shareholder value. Our strategy gives me confidence, and I believe that as a team we can produce durable long-term value for shareholders through rigorous capital allocation and disciplined execution; I'm now glad to walk you through our third quarter results, which show steady commercial execution and financial discipline. Revenue from our non-COVID portfolio grew nicely, and the combination of product mix, productivity gains and cost discipline produced margin expansion while still allowing us to keep investing steadily across our strong pipeline. Given how we've performed this year, we feel confident enough to lift our full-year 2026 revenue guidance and to both raise and narrow our adjusted diluted EPS guidance. Now let me move to the results. Revenue in the third quarter of 2026 came in at $16.6 billion, which was better than we had anticipated. We achieved robust 7% operational revenue growth from non-COVID products, with key brands in the U.S. and certain international markets leading the way, though that was partly offset by reduced revenues from COVID-19 products. On the bottom line, diluted EPS as reported for the third quarter of 2026 was $0.56. Adjusted diluted EPS came in at $0.87, topping what we had expected, and that figure absorbs a $0.10 charge related to the Innovent transaction. The beat stems from disciplined spending and better productivity across the company, even while we are raising investment behind future growth drivers and moved several Phase III study stocks forward. Revenue in the quarter got solid contributions from adequate <<inaudible>>, the Venecal family, Nurtec and our brand, whereas COVID-19 products and the Prevnar family were down over the quarter. Products we have launched or acquired generated $3.8 billion in revenue, expanding 32% operationally during the quarter, driven largely by Padcev, which added $265 million, Nurtec, up $135 million, and <<inaudible>> at $114 million. We continue putting money into this product group to ease LOE pressures in the years ahead. Results for this quarter also demonstrate tangible movement toward our aim of getting back to growth around the end of the decade. Staying disciplined on costs and continuously optimizing throughout the company—our manufacturing footprint included—remain priorities; we are achieving substantial progress on productivity efforts and are still on course to realize almost all of the projected $7.2 billion in net savings by the close of 2026 under our ongoing cost improvement programs. As we mentioned last quarter, we are launching the next stage of these programs to generate an expected $2.5 billion more in net cost savings between 2027 and 2029; those savings underpin stronger operating efficiency and support our margins. Meanwhile, we keep directing resources toward pipeline programs we see as having the strongest shot at producing significant advances for patients and building long-term value for shareholders. Adjusted gross margin for the third quarter was 77%, mainly because of a favorable product mix and sustained cost management. Turning to adjusted operating expenses, which totaled $6.8 billion, adjusted SI&A expenses grew 2% on an operational basis. Part of that reflects a smaller favorable adjustment related to U.S. health care reform fees than we had a year ago, partially offset by lower targeted marketing and promotional spend on growth drivers, along with continued cost productivity gains. Operationally, adjusted R&D spending rose 18%, which includes the planned investment we're making in priority oncology and obesity programs — among them, several Phase III trials getting underway. Acquired in-process R&D declined 52% on an operational basis, largely driven by a $650 million charge this quarter associated with the Innovent transaction, compared with a $1.35 billion charge in the same quarter last year tied to the 3SBio transaction. Our adjusted operating margin came in at 36% for the third quarter of 2026, which reflects effective cost management, strong performance in non-COVID revenue and greater investments in the business — and I'd note that it was tempered by the AIPR&D charge connected to the Innovent transaction. And as I mentioned earlier, adjusted diluted EPS for the third quarter was $0.87. Thanks to how we've performed so far this year — with our non-COVID products continuing to grow and our disciplined execution — we're lifting our full year 2026 revenue guidance by $1.5 billion at the midpoint, bringing it to a range of $62 million to $64 million. We're reaffirming that we expect roughly $4 billion from the COVID products, with most ComeaNatio revenues anticipated in the fourth quarter, in line with the vaccination season. Accolade utilization will keep tracking infection rates and treatment demand; on top of that, we now expect full year 2026 R&D expense to land between $10.8 billion and $11.8 billion. We're raising and narrowing our full year 2026 adjusted diluted EPS guidance to a range of $2.95 to $3.05. At the midpoint, that's a $0.10 increase, even while we absorb the $0.10 per-share impact from the Innovent transaction. All the remaining elements of our financial guidance are being reaffirmed. This refreshed outlook shows our confidence in progress on non-COVID products through our cost improvement initiative, an expectation that adjusted gross margin for the full year will land in the mid-70s percent range, and continued investment in our priority pipeline programs. Moving to capital allocation: our priorities there are the same as before — we put money into the business at appropriate returns, maintain another time, grow our dividend, and deliver shareholder returns, all while keeping flexibility for future value-enhancing actions, including share repurchases. After the Innovent deal wrapped up during Q3, we now have roughly $6 billion in BB capacity. Across the first nine months of 2026, we put $9.2 billion into R&D, both internal and external, and sent $7.3 billion back to shareholders via our quarterly dividend. Operating cash flow for the third quarter of 2026, year to date, came in at $8.8 billion, and leverage finished the quarter at 2.6x — a touch under our 2.7x target for 2026. Given what's on the horizon, we'd expect leverage to hover around current levels, maybe edge up a bit, as we go through the LOE transition. Our priority remains a strong financial footing while we continue funding innovation and shareholder returns. To sum up, I want to leave you with two main points. First, operational excellence. Our non-COVID product continued to perform strongly, delivering 7% operational growth, while our launched and acquired product rose 32% operationally—further proof of our strength in capabilities and consistent execution. Second, financial discipline. We're boosting operating efficiency while enabling greater pipeline investment in program waiver offers the greatest potential for patients and shareholders. All together, this performance demonstrates that we're executing our strategy, managing the upcoming LOE transition, and strengthening the foundation for a return to growth toward the end of the digital. With that, I'll turn it over to Chris.
Thanks, Cecile. We made strong headway across each of our four therapeutic areas during the quarter just ended. I'll give you some specifics on what's happened lately with a handful of those programs, starting with Elrexfio — the BCMA bispecific that came out of our own discovery work — which has now delivered two positive Phase III results in multiple myeloma that is double-class exposed. In the most recent one, MM32, Elrexfio used as a monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus investigators' choice from among three well-established standard of care regimens. Why does that matter? Because those three standard of care options offer a clear, robust picture of the way CD38 refractory multiple myeloma gets treated today, in a patient population that continues to expand as anti-CD38 therapy moves into the first-line setting. And the results themselves were strong. At the interim analysis, over 75% of patients on Elrexfio had not seen disease progression or death from any cause, and the estimated 18-month progression-free survival rate came in at roughly 68%. Safety in MM32 matched Elrexfio's known profile and was also potentially differentiated: with infection prophylaxis measures built in from the start of MM32, rates of grade three or higher infections were lower than those seen in MM5, Elrexfio's first positive pivotal trial in double-class exposed multiple myeloma. To give you some background, those infection prevention steps weren't yet being used at the time MM5 started. They were introduced later, following early infection-related deaths that were clustered in China and two additional nations amid the COVID surge, and this influenced the trial's overall hazard ratio. Results from MM5 are anticipated at a medical conference before the end of the year, which should shed more light on both efficacy and safety. All told, these encouraging Phase III findings from MM32 and MM5 strengthen our conviction about advancing Elrexfio toward earlier treatment lines. We are assembling a persuasive argument for fixed-dose Elrexfio as a monotherapy starting at first relapse, irrespective of any prior CD38 exposure. Additionally, we have pivotal trials ongoing in newly diagnosed multiple myeloma, and if those are clinically and regulatorily successful, Elrexfio's eligible patient group may expand by roughly five times. Now moving to atirmociclib — a highly selective CDK4 inhibitor that could be first in its class. Leveraging the leadership position we built with IBRANCE, we're pushing atirmociclib forward as a possible next-generation backbone for first-line and early HR-positive breast cancer treatment. Our KAT6 inhibitor, prifetrastat, is in development for later-line use. Atirmociclib came out of our own in-house design work, aimed at improving on CDK4/6 inhibitors, which today serve as the standard-of-care backbone in HR-positive breast cancer. Safety and tolerability represent a major drawback for this drug class, and CDK6 inhibition plays a significant part in driving adverse events. Atirmociclib was engineered with the goal of getting the most efficacy possible by inhibiting CDK4 more strongly, while making it better tolerated by reducing how much it binds CDK6. The drug is 33 times more selective for CDK4 over CDK6, which compares well against the current standard of care. Data from Year 2 are what's driving excitement about atirmociclib — on the left, that's our data presented at ESMO from the Phase II FOURLIGHT-1 study, which tested atermaciclib combined with fulvestrant in patients who have HR-positive HER2-negative breast cancer. Every participant had already been treated with a CDK4/6 inhibitor. Another point worth noting: 92% of the people in the atirmociclib arm were randomized within 3 months of discontinuing a CDK4/6 inhibitor. When measured against investigators' choice of fulvestrant or everolimus plus exemestane, the atirmociclib regimen reduced the risk of disease progression or death by 40%. For a population where the disease is highly refractory or resistant, these findings boost our confidence in the ongoing Phase III study of atirmociclib against investigators' choice of CDK4/6 inhibitor in the first-line setting. On the right side, we present data from our Phase II atirmociclib study in early breast cancer. When atirmociclib was given with letrozole, complete cell cycle arrest occurred in 88% of participants' tumors, compared with just 18% for letrozole alone. These findings support our plan to pair atirmociclib with giredestrant, a selective estrogen receptor degrader, in a Phase III early breast cancer trial that we expect to begin within the next few months. This study's design has been coordinated with regulators, and it builds on the anticipated approval of giredestrant in this setting. This slide highlights safety and tolerability information together with findings from pivotal trials of the three approved CDK4/6 inhibitors plus fulvestrant. These comparisons are across trials. As a result, no definitive conclusions can be reached; the data further suggest that high selectivity leads to better safety and tolerability, which supports continuous dosing, excellent adherence, and potentially greater efficacy. Grade 3 or higher neutropenia was numerically less frequent with atirmociclib than with any approved agent, and no grade 4 neutropenia was reported. Any-grade diarrhea was lower than with atirmociclib and similar to palbociclib and ribociclib. Adverse events led to dose reductions in 14% of patients on atirmociclib, versus 32% to 43% for the approved agents. Now on tivunatamig: this PD-1 VGF bispecific antibody, which we see as potentially best-in-class, is being pushed forward through a broad program — more than 1,200 patients have been treated worldwide, with a consistent safety profile — including two Phase III trials now underway, and two more Phase III trials that should start this year. The updated results presented at ESMO reinforce our confidence as we broaden tivunatamig's development. At SITC 25 and after, the confirmed response rate for the pivotal dose of tivunatamig combined with doublet chemotherapy in the ongoing Phase II trial has climbed by about 20 percentage points among first-line non-squamous and squamous non-small cell lung cancer patients; it now sits near 80%, which is higher than what tislelizumab plus chemotherapy achieved in this study. For both histologies, median progression-free survival came in at close to 14 months—an improvement of around 4 to 5 months over the comparators. One thing worth highlighting: the efficacy we saw with tislelizumab lined up with what earlier Phase III trials had shown for pembrolizumab, the leading PD-1 antibody, and that reinforces why the control arms are meaningful. We were also encouraged by how tivunatamig's efficacy and safety stacked up against Phase III data for ivonescimab, the PD-1 VGF bispecific antibody, though we keep in mind the limits of comparing across trials. Turning to I&I: tilrekimig, a potential first-in-class trispecific antibody, was designed in-house to hit several complementary drivers of type 2 inflammation at once — IL-4, IL-13 and TSLP. Phase II results in atopic dermatitis give compelling proof of concept. When you look at the highest monthly doses, tilrekimig produced a response rate adjusted for placebo of roughly 50% on EASI 75, which means an improvement of 75% or more on the Eczema Area and Severity Index. Cross-trial comparisons do have their limitations, but this Phase II data points toward possible superiority over dupilumab, the biologic that serves as today's standard of care. The key secondary endpoints in our ongoing Phase III program carry enough power to test that hypothesis in a head-to-head setting; on the safety side, tilrekimig showed a favorable profile at subcutaneous doses reaching 400 milligrams given once every 4 weeks, and the observed frequency of conjunctivitis and injection site reactions came in below the rates reported with dupilumab and similar to placebo. Beyond atopic dermatitis, tilrekimig represents both a pipeline and a product opportunity, going after pathways that approved therapies have already validated across nine different diseases, with late-stage studies underway in severe asthma and moderate-to-severe COPD. Now let's discuss our pneumococcal conjugate vaccine program, which could end up being the best in its class. We're building on the effectiveness and safety record that Prevnar has established over more than 25 years. Our next-generation candidates are designed to provide leading coverage across serotypes and invasive disease. On the pediatric side, BCB 25 produced strong Phase II results: for all 20 serotypes that it shares with Prevnar 20, it met the meth-olose-4 IgG criterion that has historically been used to establish noninferiority. Because Prevnar 20 received pediatric licensure in 2023, the FK established an updated and more stringent 1.5-fold noninferiority criterion, and that criterion is built into the design of our Phase III trial. With the Phase II data and the narrower confidence intervals we anticipate from a far larger Phase III sample, modeling projects that this threshold will be satisfied for at least 22 of 25 serotypes in our pivotal trial, when considered alongside the sero response data, the functional OP test, and the totality-of-evidence approach to licensure. These findings give us confidence as we work toward delivering a best-in-class pediatric pneumococcal vaccine that protects against serotypes responsible for an estimated 84% of invasive disease cases among U.S. children under 5. That represents an incremental gain of roughly 25 percentage points compared with Prevnar 20. Our Phase III program is well underway, and the Phase III lot-to-lot consistency study is already fully enrolled. For grown-up patients, PCB 35 takes the improved serotype three approach that PCB 25 helped us confirm and applies it to additional important serotypes, and we anticipate launching a Phase I trial during this year. As we look forward across the coming twelve months, we anticipate a robust rhythm of regulatory rulings, data disclosures and pivotal trial launches. Among these is a disclosure from MEVPRO-1, which, given the present event rate, is now anticipated during the first quarter of 2027. Should it succeed, MEVPRO-1 might support an approval for mevrometostat — our internally found, potentially first-in-class EZH2 inhibitor aimed at prostate cancer — broadening our franchise. With that said, I'll return the floor to Albert.
Thank you, Chris. To wrap up, commercial momentum across our key growth brands is being driven by operational excellence. And I'd note, importantly, this includes our launch products as well as acquired ones. Our capital allocation strategy, by contrast, is built to generate shareholder value over the long term. Meanwhile, progress in our late-stage pipeline — with a significant number of pivotal readouts anticipated in the near term — is strengthening our chance to extend leadership in key areas and make a difference for patients. I'm confident Pfizer is well positioned for growth towards the end of this decade, and for creating long-term shareholder value. We have line of sight to our aim of delivering a risk-adjusted high single-digit revenue CAGR and from year-end 2008 through year-end 2033; now we will move to Q&A. And operator, please assemble the queue.
I have just a couple of pipeline questions. Perhaps starting with the trispecific tilrekimig: how are you thinking about positioning this one in atopic derm, as you weigh, I suppose, first-line against second-line use, and maybe just consider the very strong data you presented versus a very well-entrenched standard of care? And perhaps as a second part of that, could you just talk about the time lines for the indications beyond AD that you're pursuing? The second question then is just pivoting over to the upcoming Phase I/IIa amylin and combo data that we're going to see here; can you just help set some expectations about how you're thinking about that data, and then the type of titration schedule that's being used in that study, just to help us kind of frame out what we're going to see with that readout.
No. Thank you. Chris, would you like to cover the time lines of trispecific and, of course, the amylin and berobenatide questions. And then maybe Alexandre, you can speak a little bit about the commercial positioning.
Thanks a lot for asking that. As you're aware, the Phase III program for recommend in atopic dermatitis II studies has now begun. A head-to-head trial against dupilumab is among those studies, and we've also launched the Phase II/III study — a continuous design for COPD — along with Phase III studies in severe asthma, with readouts expected in 2028 and 2029. On amylin GLP-1, the SOLIS study, as you know, has now fully recruited; that's the robustly designed Phase IIb trial of amylin as a single agent and amylin plus berobenatide at different doses and with different titrations. Efficacy results from that study should come in the second half of 2027. For the ongoing Phase I — Phase IIa study, an update will be provided at the end of this year, bearing in mind that it was designed for safety and PK clinical pharmacology rather than efficacy.
And then what about the positioning of the trispecifics?
Chris, thanks for those questions. I think we're all aware this is a really big category. What we've come to understand through Sibinco and our broader dermatology franchises is that many patient profiles need different kinds of therapy; and we see that clearly with the <<inaudible>> this is the map, and we notice some patients actually shift from one to the other, they drop off. There's considerable circulation among those patients. We're building capabilities in the U.S. and internationally, and we see good progress being made. So for example, as you saw this quarter, internationally we hit around $100 million combined across our two dermatology assets for the quarter. So we're starting to have a solid base and, as I said, as we move into the study result, we'll be able to actually capture some of those lapsed patients and naive patients with a very specific profile that we're defining. So first-in-class, strong efficacy and clearly unmet medical need in the category.
Thank you very much. Next question, please.
Yes. I'd also like to congratulate Cecile on becoming Pfizer's new CFO and say I'm looking forward to working together. My question concerns U.S. net price in the third quarter and beyond. Could you speak to any gross-to-net benefits to net sales in Q3, including anything from 340B scrubbing, and talk about what U.S. net price prospects look like in the near term?
Thanks very much. First, thank you for your good wishes. Regarding pricing in Q3, aside from the impact on adequate, which we had anticipated, we began in Q3 with the January price decrease. During Q3, I’d say our gross-to-net dynamics didn’t shift in any truly significant way. What we’re seeing in results is largely the result of a robust market and volume, not from what’s happening with the growth unit. Looking ahead—and we're not making any 2027 comments today, obviously—our 2027 guidance will clearly take into account the different dynamics we're seeing, including IRI with two of our products launching in 2027, plus all the dynamics surrounding the 340B impact and changes, among them a credit rebate model that begins in January, and of course some of the MFN impacts that follow the agreement we have in this environment. But to sum up, the performance through Q3 really reflects strong execution rather than gross-to-net dynamics that won't persist.
Very well. Thank you very much. next question, please.
Albert, over the past couple of years there has clearly been considerable progress when it comes to SG&A improvements, and I recognize that. It isn't a step function, but improvement has occurred. Yet I remember Dave saying, before he moved on, that the bulk of the total net cost savings of $7.2 billion would be delivered by the end of '26. So looking now at the Pfizer P&L, I see SG&A plus R&D was roughly $24.5 billion back in 2022, and it's roughly the same in 2026 as well. And I recognize that R&D has risen somewhat and SG&A has come down somewhat. But the broader OpEx dynamics remain broadly in that $24 billion to $25 billion camp; and I suppose, how do you think about that as we head into dividend integrity, the cost lever as we head into the Padcev race?
Cecile, why don't you take this question?
Right, and like I said before, we remain on course to deliver the $7.2 billion in savings that we put in place under the first phase of our cost improvement programs. Those savings came from various areas: first, our manufacturing footprint on the cost side, and second, R&D, though that was reinvested, and we are in fact stepping up our R&D investment to back the pipeline products and programs we have, along with the acquisition we completed, obviously. Then on the SINA side, it's mainly from commercial and marketing expenses plus SG&A. So that's what we're seeing today in our operating expenses, and I'd tie that to just the third quarter, which had some one-time dynamics that pushed SINA up. Based on guidance, we still expect a decline in SINA compared with last year. So that's the first piece I'd mention. Looking ahead, we've announced the second phase of the program, with $2.5 billion in savings across both SG&A and, in our case, manufacturing. Those will turn into savings, so we expect them to translate through and cushion the margin erosion from the LOE transition in 2027 to 2029.
Just a few things. I recall that back in the spring you had roughly a 45, 50 patient biomarker analysis on your stat sticks. And a decision was going to be made about moving from stage 1 into stage 2. Any update there on that program? And really, how are you thinking about tork reduction and biomarker reduction compared with what we've seen from some of the degraders? Then on your GLP-1 amylin, I believe your Phase I/II, you just updated on clinic trials to 201 patients, and I think originally it was planned to be closer to 400 — any color on what drove that decision with the amylin GLP-1 combo with Metsera?
Chris, both of those questions are for you.
All right, thank you so much. So first, on STAT6, which is potentially a first-in-class oral STAT6 program — I appreciate the question. This is a very important area for us, or for the I&I portfolio. As we mentioned before, we have adapted that program so that it includes some additional DDI studies. So a readout for STAT6 should come your way this year. Turning to the amylin and berobenatide: as I said earlier, the SOLIS-1 study has completed recruitment in full, and that study <<inaudible>> out at the end of next year; and the Phase I/IIa study was adapted for the extra PK studies that we are conducting; but there really is nothing — nothing material in the way of changes to the trial.
Back to the pipeline for a moment — we saw that you put up a new Phase I trial for your PIK3CA inhibitor on <<inaudible>> last week. I caught your comments on atirmociclib and your KAT6. I'm wondering whether you could speak to how that asset might slot into the wider breast cancer strategy? Then a second question, possibly from ESMO — we saw the Volga, the AstraZeneca release, which might hint at less need for, or fewer cycles of, Padcev in bladder cancer patients. Any reaction to that data, and what it could mean — how do you think Padcev use may develop going forward?
Yes. First, on the PI3K — we began a Phase I study of a PIK3CA inhibitor discovered internally; a reminder that gedatolisib with salute is also a medicine we discovered ourselves. There's an ongoing trial with relay using the PIK3CA alpha-pan, alpha-isoform selective inhibitor, and in advanced settings also combined with atirmociclib. What's advantageous about atirmociclib is that we don't observe DDIs, which has been the experience with every other CDC paired with PIK3CA. So that's potentially a meaningful advantage — as you said, up to 40% of breast cancer, positive breast cancer, and up to 20%, 25% of two positive breast cancer will carry a PIK3CA mutation. So for us it's an important area. The second question concerned the bulker data. I'll begin briefly. First, this strengthens the case for Padcev in muscle-invasive bladder cancer. It strengthens the case for Padcev combined with the PD-1 in muscle-invasive bladder cancer. It also strengthens our confidence in the study — we've just launched 309, which is bladder-sparing Padcev pembrolizumab in a bladder-sparing setting, plus the planned Phase III trial with Padcev plus tivunatamig, which should also begin later this year. I'd just like to remind you on the BARDA study: this was a no cisplatin eligible population, pathological complete remission was lower than what we've seen with pembro plus Padcev, which matters, including slightly lower event-free survival. And most importantly, this is a curative setting, so it isn't yet clear which patients can be escalated; that's an important proposition. Who can you actually give less therapy?
Now that you've taken over the capital allocation framework that our predecessor basically put in place, how are you thinking about the marginal dollars you're able to invest from here across internal R&D, another bolt-on, you mentioned BD capacity, deleveraging, and eventually restarting buybacks — where do you see the highest prospective return for shareholders right now?
Our priorities are clear, and they aren't changing from what was already in place. I'd say they are — we have a solid plan that gets us through loan poster. So our priorities are impact for growth, maintaining our dividend over time, and then keeping a strong balance; so during the LOE period, our operating cash flow, financial assets, and access to capital markets will give us the ability to keep investing and maintain a dividend. As we move post LOE target, our operating cash flow grows along with the levers, and we have other options for continuing to increase shareholder value. And in that situation, share repurchases become once again one of the levers we have in order to keep enhancing the shareholder right.
Thank you very much, next question, please.
I have two questions. First, with the pushout of MEVPRO-1, did anything change regarding the timelines for MEVPRO-2 and -3? That is my first question. My second one is for Cecile. You joined Pfizer while Warner-Lambert was in the process of being consolidated, and you have been through the Pharmacia acquisition, <<inaudible>> and Seagen, plus a lot of BD deals, Eliquis among them. One could make the case that Pfizer's most successful products have come via deals; and in each of those years, just like now, Pfizer but its pipeline is very good. So with that history in mind, why wouldn't Pfizer pursue another large deal as its primary focus? Or would you argue the pipeline today is significantly stronger than at any point in the last 25 years?
Good question. Cecile, what do you think?
Thanks. That was a record — I showed up with wires and not — so I lack the background on every deal. Still, I'd say Wires ranks among our finest acquisitions, and across the last 25 years I've watched Pfizer transform and our pipeline clearly grow stronger. So here's how I'd frame our priorities, right? As Albert said again earlier, we've put very substantial money over recent years into our main transaction and major acquisitions, and those are already helping drive success today. When it comes to Padcev and MarTech, there's still substantial opportunity sitting in the pipeline, at Seagen and at Metsera. That leaves us plenty to do on the commercial side and on the RT side alike. So as we think about BD going forward and weigh where our capital should go, we're concentrating on smaller bolt-on deals — ones that fit neatly alongside the big, rich portfolio we already hold across our four therapeutic areas. Regarding the BD acquisition, it clearly fits our strategy—it extends what we already do well and, of course, delivers the financial returns, the appropriate return, that we would expect.
Thank you. Chris, would you like to say a bit about the MEVPRO timelines? And since there is interest in the product, perhaps Aamir, you could also mention a few things regarding the potential.
Thanks a lot. I’ll keep this short. Since our last discussion on this, the timelines for MEVPRO-1 and MEVPRO-2 have been revised—just as a reminder, these are event-driven studies, meaning they’re based on when we anticipate events to occur. So MEVPRO-1 will now read out in Q1 2027, and MEVPRO-2 in Q3 2027; and as you saw at ESMO, we have additional data, including a compelling 8.9 months PFS. Just to correct that, MEVPRO-2 is actually Q4 2027, per the update on clinicaltrials.com.
And I believe one is expected around February, if I remember right. That's what the projections show at the moment, given how events are accumulating. And why are we so enthusiastic about MEVPRO when it comes to the commercial opportunity?
There are probably three reasons we feel enthusiastic. First, I'd like to remind everyone that although our existing commercial presence is based in the U.S. together with Astellas, MEVPRO represents for us a completely worldwide chance both in the U.S. and beyond it. That is quite meaningful and thrilling. Second, as Chris noted, with MEVPRO-2 and -3, and across MEVPRO-1, -2 and -3, we believe there is potential for MEVPRO to become a franchise spanning multiple indications. That provides us with a great deal of room to compete. And last, when we consider the overall patient populations, we are discussing more than 50,000 in the U.S., nearly 50,000 across the EU plus the U.K., a further 14,000 in Japan, and 30% of that population might be served even with Metro I. So there is a substantial patient population, a worldwide chance, and clearly a field where we possess deep commercial expertise — those are what make us enthusiastic about it.
Thank you, Aamir. And it's easy to overlook that with XTANDI—one of our largest and most robust products—we essentially hold half of the U.S. XTANDI business, and that's all. In this case, we'll have coverage across the entire United States as well as the full global international market.
There are just two things I want to cover. The first is the bigger picture, Albert, from a policy standpoint. I realize it's obviously hard to have certainty, especially given today, but when you look ahead to 2027, what do you think about the possible risks of MFN changes, or maybe increased scrutiny of the prior OUS agreements? Then the second question is for Chris on berobenatide. You've studied — there are sort of a lot of studies across the metabolic indications and beyond obesity and diabetes, so I'd like your thoughts on expanding berobenatide as a combo strategy into inflammation or neuroscience or even oncology, for instance. Obviously, the science on GLP-1 synergies is really evolving here.
And really, thank you, Geoff. From the policy angle, clearly policy has a big effect on our industry, and we're watching it very carefully. We're waiting to see what happens today in the elections. But I think that, in any case, it looks like we'll have a split government, so I don't think many things can move legislation wise, and I don't expect any changes in MFN. I think the agreements are signed and run until the end of this government's term. And I expect there will be renewed interest in the Congress to investigate several things. But frankly, I don't expect policy same. It's a very big contract vis-a-vis what I was telling you a year ago. In 2025, I was really scared about the implications that either tariffs or MFN could have. I think through the successful navigation of those issues, we brought stability that is now projected to last and has brought, I think, this confidence back to the investors to invest in the industry in our sector. Now with that, I'll turn it to Chris to comment on the GLP-1 and other things.
Yeah, I’ll jump in quickly. So at the outset, our aim is to get berobenatide established globally as a monthly subcutaneous GLP-1 for obesity that could be potentially best-in-class. We’re beginning — as you’ve now seen, there are additional studies for knee osteoarthritis and also for obstructive sleep apnea with or without PAP — and we’ll announce further Phase III studies over the coming months. In 2027, you’re absolutely right. We’re hoping to announce some additional studies that look at the backbone of our portfolio, including Ignite, retention in oncology — you’re right, that’s an interesting area. And you’ll also see acceleration of Phase I programs and current programs that are preclinical and highly differentiated in this space. Thank you.
All right. Let's take the next question.
I have two; so when you consider the Siwen Biosciences GLP-1 launch in China, how are the obesity and diabetes markets each performing thus far? And how does that influence your thinking regarding the commercial opportunity for berobenatide OUS? And then regarding the vaccine line, could you update us on the regulatory path forward after the recent submission in Europe? How are your discussions with FDA going? And are there any meaningful differences between the FDA and EMA?
I'm not certain I grasped the second question.
Lyme disease and Lyme vaccines.
Yes. So Alex, thank you very much, Alexandre. Alexander, could you perhaps say a bit about our GLP-1 in China? And what do you anticipate from it?
That's right, and thanks for the question. As you mentioned, Alex, we launched oblate in China at the end of April this year, and we're pleased with how things are going; through the Egnoglutide launch in China we're gaining a great deal of insight. What's becoming clear to us is that within the overall chronic weight management categories there are very distinct segments — patients who all meet the definition for product weight management, yet some have a more esthetic-driven purpose, with a very different product profile they're seeking, and the way they acquire the product is actually quite different from the other end of the spectrum, which is very heavy people seeking much more efficacy and tolerability — that becomes a second fair point. So clearly, what we're learning confirms our strategy: success in Polypoint management requires a portfolio. A portfolio is also necessary because you'll need to activate all those different channels, and the cost of activating those channels gets amortized across the portfolio. Those are very, very key confirmations of our strategy. Now, specifically on ecnoblotide: as you know, we understood from the getgo that succeeding in chronic weight management in China, in particular, requires two things. Of course, we have a good profile — a very competitive profile — but you also need type 2 diabetes, since it opens the hospital channel and, under local regulations, the e-commerce channels as well. I'm very happy to say that since the end of October we've actually received approval for our type 2 diabetes, which opens up that channel. Second, our competitors also have access to reimbursement, and that matters greatly for competing effectively. So I'm also very happy to report that since June we've passed the — an RDL committees, and now we expect the final review by the end of this month. So hopefully we can bring our product into the overall hospital reimbursement system. Those two things combined will really mark the start of our market penetration.
From where I sit, it is really interesting to observe how differently the commercial model works around obesity compared with anything else. For us, it genuinely brings back memories of the Viagra launch, since there are many parallels. Consumers will pay out of pocket for products they see value in. Whether or not they get reimbursed makes no difference, and that produces a dramatically different scale across international markets. The second point was that, given the consumer character of these loans, e-commerce and the internet did not develop the same way with Viagra, which was essentially the first product you could get online, and that plays a key role; and naturally, we are already quite far into that space, even more so than if we had already brought an obesity product to market, because our vaccines, our <<inaudible>> COVID, and our migraine product all have a substantial channel through Pfizer for all, which is, let's say, our consumer web portal to the website. So I think it's — we are learning a great deal right now in China, after having learned a great deal with our Viagra experience. And to add one more dimension, AI is transforming how promotions are carried out at present, and not just at the physician level, but actually, even more significantly, at the patient's level. So we are learning a lot, and we are very pleased to be entering this market, because I think we — it's — it suits our capabilities. With that, I will invite Chris to comment on the Lyme business.
Appreciate the question. We're all aware of how often Lyme disease occurs. Its burden is now growing around the world. The EMA has validated the MAA for the Lyme disease vaccine candidate from Pfizer and Valneva, and with that validation, the CHMP will now start assessing the MAA, and the CHMP is expected to give an opinion on marketing authorization in 2027. We have also filed in Canada at this point, and our talks with the FDA are continuing, and we should give an update on that in Q4 of this year.
Alexander, do you have anything to add here?
Yeah. No, I really think this is a very exciting opportunity. Let me just remind everyone that we already operate an SME franchise in Europe, and we understand how to activate tickborne populations in those endemic areas, since we have a sales force and we have a commercial play with pharmacies. So we're very excited about this opportunity. Awareness among the population is significantly higher than what we see in SME; so given that we've built these commercial muscles, once the approval comes, we're very much looking forward to the chance to commercialize this vaccine.
Disease awareness in the U.S. is, of course, climbing sharply at the moment, since we are indeed seeing more severe cases and a rise in incidents; therefore we look forward to wrapping up the talks with FDA and getting our filings submitted. Let's move on to the next question, please.
Perhaps a couple of fast pipeline questions for Chris. Regarding MEVPRO, you folks remain quite bullish. I understand a formulation adjustment was made to reduce the Cmax and boost tolerability. Could you maybe weigh in on how you view dropouts and the formulation change in terms of driving your effect; and then concerning tilrekimig, which is trispecific and again something you're fairly bullish about. Could you just weigh in on neutralizing antibodies or ADAs, things that can be difficult with bispecifics and trispecifics, and how you view that?
On the first question about protostat, as you mentioned, for the Phase III study we did adapt to a more tolerable dose with food, where we lowered the max but see a comparable AUC to what we saw in Phase I; so we're quite confident in the PK data and the dosing selected for the Phase III study. As for tilrekimig, we have not observed functional neutralizing antibodies or functional ADIs so far, and you're absolutely right that any bispecific or trispecific carries a long-term risk. But thus far, we haven't seen anything affecting efficacy. And in fact, longer-term follow-up from the studies we previously demonstrated shows us that we do not have an impact on efficacy. So, so far, so good.
Very good. Let's keep it that way if you can please. Next question, please.
Congratulations on the quarter, Cecile, and also lots of congratulations and best of luck to you. I have a couple of questions for you. First, just on 2027, I appreciate the context provided earlier on price dynamics, with respect to IRA and 340B, et cetera. But is there any additional high-level qualitative framing on other pushes and pulls next year to be aware of ahead of formal guidance? And how should we be thinking about your guidance philosophy relative to Dave broadly speaking? And then looking out longer term, you are reiterating line of sight to high single-digit revenue CAGR towards the end of the decade off of a 2028 base, as well as siding operating leverage and margin expansion given the cost realignment initiatives. But consensus numbers are not really modeling that. There does seem to be a disconnect on both revenue and the earnings line versus your own expectations. So as you examine Street forecasts, what are the key assumptions that you think are getting most mismodeled in the P&L relative to your own internal expectations as you look out towards that period?
Cecile, please make the comments on both.
Thank you, Asad, for that question and for your kind words. We'll be giving 2027 guidance around mid-December, the same as we did a year ago. So I'll just highlight the main high-level drivers we're seeing for 2027; first, obviously, is the LOE impact, not just in the U.S. with brand XTANDI and a few other products, but internationally as well, where Eliquis is coming at the end of 2026. The other thing I'd mention is that, obviously, offsetting this is the ramp-up and launch of our — the ramp-up of our launch and acquired portfolio, which, again, as you've seen, is performing very strongly and offers a growth opportunity; and then obviously pricing, including MFN, which we will reflect in our guidance; and then our cost initiative program, which will let us keep investing toward the growth opportunity that — or the growth driver we have in the SINA marketing and commercial space, and then raise productivity and deliver savings, both in commercial spend and also in general and administrative spend. So those seemed like the key trends for 2027. But again, more to come when we release guidance later on. As for our high single digit growth aspiration versus the Street, if you look at where that difference comes from, it isn't really coming from one place on one product. and our growth trajectory isn't either. So what we see as a building block for our growth trajectory, obviously, one is continued growth of our new and acquired products, not only because the market is still growing. Our penetration is still increasing. But on top of that, we're bringing new indications onto those products so we can keep addressing more patients and grow our presence in the market. The second thing is the pipeline. So while there are some obvious products making a key difference in our view versus a review obesity being one, some of the oncology products that you want, what I'd say is our growth trajectory doesn't rely on one single product or one single therapeutic area. We have a broad portfolio of products, several Phase III ongoing as well as our upcoming catalysts over the 18 to 24 months, which should give confidence to the outside world also to see the opportunity we have in bringing breakthrough to patients in a significant area of unmet need.
Thanks, Cecile. Let me add this: as CEO, when I compare what we project internally with what the street is projecting, that naturally creates for me a sense of urgency to test our assumptions, to verify whether we're right or not given the different views analysts hold. So we did that, we repeated it, and we reached the conclusion we're sharing with you: we expect a high single digit, from 28% to 33%. You know quite well where the discrepancies sit across products; and as Cecile said, they aren't only in the pipeline, which many analysts don't cover. So you have the phenomenon that out of 12, 13 analysts forming the overall picture for 2031, for some products there are only five analysts; they have this one and the others don't. So that's — this is something expected in pipeline. But we also see very large discrepancies in already launched new products, a very big difference. I'll cite just two examples where I believe people need to reassess their estimates. First, it concerns Norte, where we're already near $2 billion on this path, if you analyze it, and the Street has us at almost 2.5 by 2030. So I think a discrepancy exists there. I'll also mention another example, Elrexfio, where for a competing product the Street forecasts $5 billion and for us $600 million; we're going to present a profile that is very similar in efficacy and better in tolerability and side effects. Now it remains to be proven. But I don't think $600 million versus $5 billion is justifiable even with the current information. So I think that as more information arrives on our pipeline and readouts, I think as more information arrives on the actual performance of the new products, and that includes new launches and acquired products, I think the Street will probably begin adjusting their numbers, and there will be a conversion, costly; but with that, I think we've come to the end of our call, and I want to say that I'm very proud of our performance through the third quarter and the execution. And my thanks go to my Pfizer colleagues. As I visit with our people, and I do that in our labs and at manufacturing sites and in markets across the world, I see a team with tremendous talent, dedication, striving for breakthroughs that change patients' lives. We look forward to sharing additional updates about our progress, and thank you for joining our call today, and thank you for your interest in Pfizer.
Thanks. That takes us to the close of today's meeting. We appreciate the time you've given and your participation. You can disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Pfizer Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Pfizer Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.